ARTELO BIOSCIENCES, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $5.4M | $6.0M | $5.7M | $4.3M | $3.8M |
| Operating expenses | $11.4M | $10.1M | $9.9M | $10.3M | $9.4M |
| Operating income | -$11.4M | -$10.1M | -$9.9M | -$10.3M | -$9.4M |
| Interest expense | $194,000 | $0 | $0 | $5,000 | — |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12.9M | -$9.8M | -$9.3M | -$10.1M | -$9.4M |
| Balance Sheet | |||||
| Cash and equivalents | $600,000 | — | — | $6.9M | $12.2M |
| Current assets | $695,000 | $2.6M | $11.0M | $18.3M | $24.6M |
| Total assets | $2.8M | $4.7M | $13.0M | $20.4M | $28.3M |
| Current liabilities | $4.0M | $1.8M | $1.3M | $998,000 | $1.0M |
| Total liabilities | $4.1M | $1.8M | $1.3M | $1.0M | $1.1M |
| Stockholders' equity | -$1.3M | $2.9M | $11.8M | $19.4M | $27.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$8.5M | -$8.3M | -$8.2M | -$8.0M | — |
| Stock-based compensation | $1.1M | $818,000 | $1.0M | $2.5M | — |
Shares outstanding 2.3M · Free float 68.5%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.